FLT3 and acute myeloid leukemia: In Table 2, a phase III RATIFY placebo-controlled study investigated use of induction and consolidation chemotherapy combined with midostaurin, followed by maintenance with midostaurin in 717 patients with newly diagnosed AML with FLT3 mutation [59].